Stanley Laman Group, Ltd. Neurocrine Biosciences Inc Transaction History

Stanley Laman Group, Ltd.

$555 Million
Q3 2025

A detailed history of Stanley Laman Group, Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Stanley Laman Group, Ltd. holds 25,354 shares of NBIX stock, worth $3.67 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares

25,354

Previous 42,521 40.37%

Holding current value

$3.67 Million

Previous $5.34 Million 33.4%

% of portfolio

0.64%

Previous 0.99%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 22, 2025	SELL	$123.98 - $146.67 $2.13 Million - $2.52 Million	-17,167 Reduced 40.37%	25,354 $3.56 Million
Q2 2025 Jul 29, 2025	BUY	$87.54 - $128.18 $863,319 - $1.26 Million	9,862 Added 30.2%	42,521 $5.34 Million
Q1 2025 Apr 16, 2025	SELL	$107.22 - $153.29 $1.02 Million - $1.46 Million	-9,499 Reduced 22.53%	32,659 $3.61 Million
Q4 2024 Jan 29, 2025	BUY	$111.62 - $139.44 $516,465 - $645,188	4,627 Added 12.33%	42,158 $5.75 Million
Q3 2024 Oct 21, 2024	BUY	$114.58 - $153.15 $1.16 Million - $1.54 Million	10,088 Added 36.76%	37,531 $4.32 Million

Q2 2024 Jul 18, 2024	BUY	$130.86 - $143.19 $3.59 Million - $3.93 Million	27,443 New	27,443 $3.78 Million
Q3 2018 Oct 30, 2018	SELL	$98.88 - $125.85 $8.89 Million - $11.3 Million	-89,884 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$75.3 - $105.99 $807,818 - $1.14 Million	10,728 Added 13.55%	89,884 $8.83 Million
Q1 2018 May 01, 2018	SELL	$75.88 - $92.43 $758,041 - $923,375	-9,990 Reduced 11.21%	79,156 $6.56 Million
Q4 2017 Feb 09, 2018	BUY	$58.53 - $77.59 $1.97 Million - $2.62 Million	33,723 Added 60.85%	89,146 $6.92 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $2.66 Million - $3.4 Million	55,423	55,423 $3.4 Million

Others Institutions Holding NBIX

# of Institutions

724

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Stanley Laman Group, Ltd. with notifications on news.

Account

Stanley Laman Group, Ltd. Neurocrine Biosciences Inc Transaction History